MetaCap

HCW Biologics (HCWB) vs Lakewood-Amedex Biotherapeutics (LABT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

HCW Biologics is the larger company by market cap ($2.4 million vs $2.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HCWB-51.98%LABT-71.18%
+7%-38%-82%
Oct 7, 20261 yearNov 20, 2026
HCWB-53.18%LABT-68.69%
+4%-37%-78%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HCWB versus LABT key metrics
MetricHCWBLABT
Share price$0.7491$0.2449
Market cap$2.35M$2.19M
1-day change+1.90%+15.03%
EPS (TTM)$-9.09$-5.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.23K—
Revenue growth (YoY)-97.89%—
Net income (latest FY)$-7.96M—
Gross margin20.00%—
Operating margin-24270.74%—
Net margin-14677.14%—
52-week high$23.94$98.20
52-week low$0.70$0.17
Distance from 52-week high-96.87%-99.75%
Analyst consensusbuystrong_buy
Avg. price target upside+6307.69%+4799.96%
Average volume379.38K16.14M
Shares outstanding3.14M8.95M
Employees355
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About HCW Biologics

HCWB stock →

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

About Lakewood-Amedex Biotherapeutics

LABT stock →

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

HCWB vs LABT FAQ

Which is bigger, HCW Biologics or Lakewood-Amedex Biotherapeutics?

HCW Biologics (HCWB) is larger, with a market capitalization of $2.35M compared with $2.19M for Lakewood-Amedex Biotherapeutics (LABT).

Are HCW Biologics and Lakewood-Amedex Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons